Suzanne M Morris

US Patent:

6824986, Nov 30, 2004

Filed:

Oct 6, 1998

Appl. No.:

09/167088

Inventors:

Fred D. Finkelman - Cincinnati OH
Suzanne C. Morris - Mason OH

Assignee:

University of Cincinnati - Cincinnati OH

International Classification:

G01N 3353

US Classification:

435 71, 435 75, 435 723, 435 724, 435 792, 435375, 4352872, 436506, 436507, 436512, 436513, 436548, 436177

Abstract:

The present invention involves techniques for evaluating in vivo cytokine production through the in vivo capture of secreting cytokines by labeled cytokine-binding reagents, followed by in vitro measurement of serum levels of captured cytokine. The methods of the present invention make use of the ability of a neutralizing antibody to a cytokine, when injected into a person or expierimental animal, to bind that cytokine and prevent its catabolism, excretion, or binding to a cytokine receptor. This causes the cytokine, which may normally have a very short in vivo half life, to accumulate in vivo as a cytokine/anti-cytokine antibody complex. If the anti-cytokine antibody is either labeled with a molecule that can be bound by another molecule (e. g. ; biotin, which is bound by avidin or streptavidin), or is itself capable of being bound by another molecule (e. g. ; a rat anti-cytokine antibody could be bound by an anti-rat immunoglobulin antibody), and the cytokine can also be bound by an antibody that recognizes a site distinct on the cytokine molecule from the site bound by the injected, neutralizing antibody, than the concentration of the cytokine/anti-cytokine complex in serum or other biological fluid can easily be assayed by a modified ELISA.

US Patent:

20190365785, Dec 5, 2019

Filed:

Feb 19, 2018

Appl. No.:

16/476608

Inventors:

- Cincinnati OH, US
Suzanne Morris - Mason OH, US
Unni Krishna Sri Rama Lingeswa Samavedam - Cincinnati OH, US
Simon Patrick Hogan - Witmore Lake MI, US

International Classification:

A61K 31/575
A61K 31/155
A61K 31/216
A61K 39/35
A61P 37/08

Abstract:

Provided are methods of preventing or suppressing an allergic reaction to food by administering an inhibitor of the unfolded protein response (UPR) and uses of a composition comprising an inhibitor of the UPR for treating or preventing a food allergy for manufacture of a medicament for treating or preventing a food allergy.

US Patent:

20180000837, Jan 4, 2018

Filed:

Sep 14, 2017

Appl. No.:

15/704097

Inventors:

- Cincinnati OH, US
Marat V. Khodoun - Mason OH, US
Suzanne C. Morris - Mason OH, US

International Classification:

A61K 31/573
A61K 31/506
A61K 45/06
A61K 31/675
A61K 31/4709
A61K 31/4439
A61K 31/4409
A61K 31/335
C07K 16/42
A61K 31/137
A61K 39/00

Abstract:

Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.

US Patent:

20150246125, Sep 3, 2015

Filed:

Feb 27, 2015

Appl. No.:

14/633305

Inventors:

- Cincinnati OH, US
Marat V. Khodoun - Mason OH, US
Suzanne C. Morris - Mason OH, US

Assignee:

UNIVERSITY OF CINCINNATI - Cincinnati OH

International Classification:

A61K 39/395
A61K 31/675
A61K 31/506
A61K 31/573
A61K 31/137
A61K 31/335
A61K 45/06
A61K 31/4439
A61K 31/4709

Abstract:

Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis.